The COVID-19 pandemic has put a huge strain on critical care resources worldwide, as systems have struggled to provide [high-quality care](https://doi.org/10.1016/S2213-2600(20)30161-2){#interrefs10} for a surge of critically ill patients. The response of clinicians and researchers---in providing care in extraordinary circumstances and in rapidly establishing research programmes to explore the potential of a range of preventive and therapeutic approaches---has been impressive. Lessons can be learned from the challenges encountered and the successes achieved as we consider future directions for critical care.

The crisis has triggered collaborative efforts to develop and implement treatments and vaccines, as seen with the launch of the Accelerating COVID-19 Therapeutic Interventions and Vaccines ([ACTIV](https://doi.org/10.1001/jama.2020.8920){#interrefs20}) public--private partnership. A range of treatments to target the virus or the host response---including small-molecule antivirals, monoclonal antibodies, and cell-based therapies---is being tested in clinical trials. Promising results have been reported for [remdesivir](https://doi.org/10.1056/NEJMoa2007764){#interrefs30}, but further developments are eagerly awaited. Testing of interventions should go hand in hand with efforts to understand the pathology, disease mechanisms, clinical features, and clinical course of COVID-19; the identification of phenotypes and treatable traits could ultimately help to facilitate a personalised approach to care. The pandemic has also brought renewed focus to the fundamentals of good clinical practice, including the need to make full use of interventions with proven benefit---eg, [lung-protective ventilation](https://doi.org/10.1016/S2213-2600(20)30127-2){#interrefs40} for acute respiratory distress syndrome (ARDS)---and to restrict the use of unproven interventions that might do harm to testing in controlled trials, as far as possible.

In low-income and middle-income countries (LMICs), the pandemic has drawn attention to the scarcity of much-needed resources for critical care; importantly, it has also emphasised the need for training and education of health-care workers, modification of guidance developed in high-income settings to establish management approaches that match local resources, and research with a focus on clinical practice in LMICs. Outside the pandemic setting, the [Kigali modification](https://doi.org/10.1164/rccm.201503-0584OC){#interrefs50} of the Berlin definition of ARDS exemplifies the pragmatic adjustments that can be made to facilitate critical care medicine in resource-limited settings. Large, collaborative initiatives such as the International Severe Acute Respiratory and Emerging Infection Consortium ([ISARIC](https://isaric.tghn.org/){#interrefs60}) have also enabled progress in the prevention and management of critical illness on a global scale. Building critical care capacity, responding rapidly to local emergencies, and tailoring diagnostic, prognostic, and therapeutic approaches to a range of settings should be a priority as we move beyond the current crisis.

The substantial heterogeneity of critical care syndromes such as ARDS and sepsis has hindered progress in identifying treatment targets and achieving positive outcomes in clinical trials. A lack of targeted therapeutics and consensus on aspects of management has meant that the needs of critically ill patients are often unmet, with some subgroups exposed to interventions that do harm. In a Review in this issue, [Kiran Reddy and colleagues](https://doi.org/10.1016/S2213-2600(20)30124-7){#interrefs70} outline advances in the identification of clinical and biomarker-driven subphenotypes of critical care syndromes, which could transform the landscape of critical care as precision medicine approaches are realised. In a second Review, [Tom van der Poll and colleagues](https://doi.org/10.1016/S2213-2600(20)30080-1){#interrefs80} consider the potential of macrolides in correcting immune dysregulation in critically ill patients, highlighting the need to identify subgroups of patients who might benefit from existing and novel compounds.

Developments in research and clinical practice will bring new challenges, but also opportunities for progress in meeting the needs of individual patients. [Large-scale research networks](https://doi.org/10.1016/S2213-2600(19)30475-8){#interrefs90} could help to accelerate patient recruitment, achieve larger samples of predicted responders, and improve the generalisability of research findings. [Adaptive platform trial](https://www.nature.com/articles/s41573-019-0034-3){#interrefs100} designs could improve the efficiency and productivity of testing. And the hope is that new approaches to clinical decision making (eg, use of [artificial intelligence](https://doi.org/10.1038/s41591-018-0213-5){#interrefs110}) and the delivery of high-quality care (eg, through [telemedicine](https://doi.org/10.1097/CCM.0000000000004190){#interrefs120}) will help to ensure that patients benefit from emerging therapeutic options.

The COVID-19 crisis has served as a stark reminder of the need for planning and preparedness to allow critical care resources to be mobilised and to enable rapid testing of diagnostic, prognostic, and therapeutic approaches to tackle new disease outbreaks. The high motivation for progress in research and clinical practice---with support from funders and policy makers---must be maintained and expanded as we look beyond COVID-19 to the full range of issues that need to be addressed in critical care medicine worldwide.
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